Tolcapone

A selective, potent and reversible nitrocatechol-type inhibitor of catechol-O-methyltransferase (COMT) for treatment of Parkinson's disease; also kills neuroblastoma (NB) cells in preclinical models by inhibition of COMT; induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma; also is a potent Transthyretin (TTR) aggregation inhibitor.Parkinson's Disease Approved (In Vitro) :Tolcapone is cytotoxic to neuroblastoma (NB) cells with IC50 values ranging from 32.27 μM for SMS-KCNR cells to 219.8 μM for MGT9-102-08 primary cells.Tolcapone (25, 50,75, 100 μM) treatment activates downstream apoptotic events in NB cells. Tolcapone induces caspase-mediated apoptosis in neuroblastoma. (In Vivo) :Tolcapone (125 mg/kg; orally) inhibits tumor growth and prolongs survival in vivo. There are no adverse events or differences in weight or behavior noted in the mice.